61 related articles for article (PubMed ID: 38573548)
1. ITGB4 is a prognostic biomarker and correlated with lung adenocarcinoma brain metastasis.
Zhang J; Li L; Luo W; Ma S; Zhao Y
Clin Transl Oncol; 2024 May; ():. PubMed ID: 38776034
[TBL] [Abstract][Full Text] [Related]
2. Identification of immune-associated biomarker for predicting lung adenocarcinoma: bioinformatics analysis and experiment verification of PTK6.
Xiong RH; Yang SQ; Li JW; Shen XK; Jin LM; Chen CY; Yue YT; Yu ZC; Sun QY; Jiang W; Jiang MZ; Wang XY; Song SX; Cao D; Ye HL; Zhao LR; Huang LP; Bu L
Discov Oncol; 2024 Apr; 15(1):102. PubMed ID: 38573548
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
4. Identification of ALG3 as a potential prognostic biomarker in lung adenocarcinoma.
Yuan Y; Xie B; Guo D; Liu C; Jiang G; Lai G; Zhang Y; Hu X; Wu Z; Zheng R; Huang L
Heliyon; 2023 Jul; 9(7):e18065. PubMed ID: 37539167
[TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.
Wang N; Zhu L; Xu X; Yu C; Huang X
Comput Struct Biotechnol J; 2022; 20():4390-4401. PubMed ID: 36051873
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analysis identifies
Yang H; Wei X; Zhang L; Xiang L; Wang P
Transl Cancer Res; 2022 Aug; 11(8):2902-2916. PubMed ID: 36093552
[TBL] [Abstract][Full Text] [Related]
8. Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer.
He D; Wang L; Xu J; Zhao J; Bai H; Wang J
Front Immunol; 2023; 14():1265865. PubMed ID: 37915579
[TBL] [Abstract][Full Text] [Related]
9. Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer.
Wang L; Du C; Jiang B; Chen L; Wang Z
Front Immunol; 2023; 14():1256740. PubMed ID: 37901223
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic Modulators as Therapeutic Agents in Cancer.
Patnaik E; Madu C; Lu Y
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834411
[TBL] [Abstract][Full Text] [Related]
11. Single-cell sequencing technology applied to epigenetics for the study of tumor heterogeneity.
Hu Y; Shen F; Yang X; Han T; Long Z; Wen J; Huang J; Shen J; Guo Q
Clin Epigenetics; 2023 Oct; 15(1):161. PubMed ID: 37821906
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer.
Jerin S; Harvey AJ; Lewis A
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509364
[TBL] [Abstract][Full Text] [Related]
13. CD4
Speiser DE; Chijioke O; Schaeuble K; Münz C
Nat Cancer; 2023 Mar; 4(3):317-329. PubMed ID: 36894637
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
